{"id":145725,"date":"2023-03-14T09:46:27","date_gmt":"2023-03-14T08:46:27","guid":{"rendered":"https:\/\/rtvnp.rs\/?p=145725"},"modified":"2023-03-14T09:46:27","modified_gmt":"2023-03-14T08:46:27","slug":"fajzer-kupuje-farmaceutsku-kompaniju-sigen-za-43-milijarde-dolara","status":"publish","type":"post","link":"https:\/\/arhiva.rtvnp.rs\/?p=145725","title":{"rendered":"Fajzer kupuje farmaceutsku kompaniju Sigen za 43 milijarde dolara"},"content":{"rendered":"<p>Farmaceutski gigant, ameri\u010dka kompanija Fajzer, potpisala je uzgovor vredan 43 milijarde dolara za kupovinu farmaceutske kompanije zigen iz Va\u0161ingtona, poznate po naprednim, ciljanim anti-kancerogenim terapijama. Kupovina kompanije Fajzer \u0107e uvrstiti u svoju ponudu \u010detiri odobrene terapije za le\u010denje kancerogenih bolesti koje su u 2022. godini donele prihode od dve milijarde dolara.<br \/>\nKompanija Sigen iz Va\u0161ingtona je pionir kompleksne terapije koja sinergetski napada i uni\u0161tava \u0107elije raka kao &#8220;navo\u0111eni projektil&#8221;, \u0161tedec\u0301i zdrave c\u0301elije.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Farmaceutski gigant, ameri\u010dka kompanija Fajzer, potpisala je uzgovor vredan 43 milijarde dolara za kupovinu farmaceutske kompanije zigen iz Va\u0161ingtona, poznate po naprednim, ciljanim anti-kancerogenim terapijama. Kupovina kompanije Fajzer \u0107e uvrstiti u svoju ponudu \u010detiri odobrene terapije za le\u010denje kancerogenih bolesti koje su u 2022. godini donele prihode od dve milijarde dolara. Kompanija Sigen iz Va\u0161ingtona [&hellip;]<\/p>\n","protected":false},"author":21,"featured_media":101320,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9],"tags":[],"class_list":["post-145725","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-drustvo"],"_links":{"self":[{"href":"https:\/\/arhiva.rtvnp.rs\/index.php?rest_route=\/wp\/v2\/posts\/145725","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/arhiva.rtvnp.rs\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/arhiva.rtvnp.rs\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/arhiva.rtvnp.rs\/index.php?rest_route=\/wp\/v2\/users\/21"}],"replies":[{"embeddable":true,"href":"https:\/\/arhiva.rtvnp.rs\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=145725"}],"version-history":[{"count":0,"href":"https:\/\/arhiva.rtvnp.rs\/index.php?rest_route=\/wp\/v2\/posts\/145725\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/arhiva.rtvnp.rs\/index.php?rest_route=\/wp\/v2\/media\/101320"}],"wp:attachment":[{"href":"https:\/\/arhiva.rtvnp.rs\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=145725"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/arhiva.rtvnp.rs\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=145725"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/arhiva.rtvnp.rs\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=145725"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}